Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

Definitive chemoradiotherapy (CRT) is the standard treatment for locally advanced unresectable esophageal cancer, but its efficacy remains unsatisfactory. More importantly, there is a lack of effective consolidation treatment after CRT, resulting in a high recurrence rate. Our previous prospective phase II trial (EC-CRT-001) demonstrated that the addition of toripalimab to definitive CRT improved the complete response rate in patients with locally advanced esophageal squamous cell carcinoma (ESCC), showing potential for enhanced long-term survival with a manageable safety profile. Nevertheless

Trial Details

NCT ID
NCT07177794
Phase
PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • toripalimab
  • capecitabine
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Histologically confirmed squamous cell carcinoma of the esophagus;
  • Locally advanced esophageal cancer classified as stage I-IVA (inoperable or patient declined surgery) or stage IVB thoracic esophageal cancer with …
  • Completion of definitive concurrent chemoradiotherapy without disease progression; radiotherapy dose of 50-50.4 Gy using conventional fractionation…
  • Enrollment window: within 1-42 days after completion of chemoradiotherapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →